<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 28 Jan 2021 16:14:25 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>CAR-T升级：OX40新装备</title><link>https://mp.weixin.qq.com/s/AlFpOUEKyjwLy1N1cPOFnw</link><description></description><content:encoded><![CDATA[CAR-T升级：OX40新装备]]></content:encoded><pubDate>Thu, 28 Jan 2021 13:24:50 +0800</pubDate></item><item><title>错过安全性终点：辉瑞JAK抑制剂Tofacitinib</title><link>https://mp.weixin.qq.com/s/JxVR4zbTXMd3wkEoDIlP4Q</link><description></description><content:encoded><![CDATA[错过安全性终点：辉瑞JAK抑制剂Tofacitinib]]></content:encoded><pubDate>Thu, 28 Jan 2021 13:24:50 +0800</pubDate></item><item><title>乙肝中和抗体脱颖而出，Vir Biotechnology股价大涨74%</title><link>https://mp.weixin.qq.com/s/jzJM5kakGkF4f7rTtgIUmg</link><description></description><content:encoded><![CDATA[乙肝中和抗体脱颖而出，Vir Biotechnology股价大涨74%]]></content:encoded><pubDate>Wed, 27 Jan 2021 06:44:08 +0800</pubDate></item><item><title>降低住院和死亡率高达70%：礼来/君实新冠中和抗体鸡尾酒三期临床成功</title><link>https://mp.weixin.qq.com/s/Wev_pQzgbeYt4Wcpv8IqPw</link><description></description><content:encoded><![CDATA[降低住院和死亡率高达70%：礼来/君实新冠中和抗体鸡尾酒三期临床成功]]></content:encoded><pubDate>Wed, 27 Jan 2021 06:44:08 +0800</pubDate></item><item><title>有症状感染保护率100%：再生元中和抗体鸡尾酒用作疫苗</title><link>https://mp.weixin.qq.com/s/r9Hctahk-qXL_O8WDnB_Yg</link><description></description><content:encoded><![CDATA[有症状感染保护率100%：再生元中和抗体鸡尾酒用作疫苗]]></content:encoded><pubDate>Wed, 27 Jan 2021 06:44:08 +0800</pubDate></item><item><title>ERBB受体家族</title><link>https://mp.weixin.qq.com/s/JZfho9O6DQTt87ifaqOCtQ</link><description></description><content:encoded><![CDATA[ERBB受体家族]]></content:encoded><pubDate>Tue, 26 Jan 2021 14:08:04 +0800</pubDate></item><item><title>四环医药收购康明百奥</title><link>https://mp.weixin.qq.com/s/6JD9eAVWiPrKazTwAfvnZQ</link><description></description><content:encoded><![CDATA[四环医药收购康明百奥]]></content:encoded><pubDate>Tue, 26 Jan 2021 14:08:04 +0800</pubDate></item><item><title>CAR-T进行时</title><link>https://mp.weixin.qq.com/s/WT5FDpIG3lqZ4alU2pv97w</link><description></description><content:encoded><![CDATA[CAR-T进行时]]></content:encoded><pubDate>Tue, 26 Jan 2021 14:08:04 +0800</pubDate></item><item><title>中国抗体技术全梳理</title><link>https://mp.weixin.qq.com/s/L0srNwWJREeN3Gc1yf64_g</link><description></description><content:encoded><![CDATA[中国抗体技术全梳理]]></content:encoded><pubDate>Mon, 25 Jan 2021 10:26:50 +0800</pubDate></item><item><title>甘李药业市值突破千亿，胰岛素龙头布局未来</title><link>https://mp.weixin.qq.com/s/MOwHcsXCYdEclC1i20VeXQ</link><description></description><content:encoded><![CDATA[甘李药业市值突破千亿，胰岛素龙头布局未来]]></content:encoded><pubDate>Mon, 25 Jan 2021 10:26:50 +0800</pubDate></item><item><title>未来已来：肿瘤新抗原疫苗</title><link>https://mp.weixin.qq.com/s/3QtoJps7fQomT6xADrrIjQ</link><description></description><content:encoded><![CDATA[未来已来：肿瘤新抗原疫苗]]></content:encoded><pubDate>Sun, 24 Jan 2021 21:12:37 +0800</pubDate></item><item><title>FDA一个月连批两款狼疮肾炎药物：Voclosporin获批</title><link>https://mp.weixin.qq.com/s/i595Nj0A8GwqbES-jCRv5w</link><description></description><content:encoded><![CDATA[FDA一个月连批两款狼疮肾炎药物：Voclosporin获批]]></content:encoded><pubDate>Sat, 23 Jan 2021 15:04:29 +0800</pubDate></item><item><title>IgA：对抗新冠病毒感染中发挥重要作用</title><link>https://mp.weixin.qq.com/s/EjOyligA_8M2-FLyeDegjQ</link><description></description><content:encoded><![CDATA[IgA：对抗新冠病毒感染中发挥重要作用]]></content:encoded><pubDate>Sat, 23 Jan 2021 15:04:29 +0800</pubDate></item><item><title>辉瑞GUCY2c/CD3双抗</title><link>https://mp.weixin.qq.com/s/xb0xtMpp1zjKmUssGeZWIA</link><description></description><content:encoded><![CDATA[辉瑞GUCY2c/CD3双抗]]></content:encoded><pubDate>Sat, 23 Jan 2021 15:04:29 +0800</pubDate></item><item><title>石药集团抗体药全梳理</title><link>https://mp.weixin.qq.com/s/esNDXS9v0I2i_caW-8D0AQ</link><description></description><content:encoded><![CDATA[石药集团抗体药全梳理]]></content:encoded><pubDate>Fri, 22 Jan 2021 19:52:58 +0800</pubDate></item><item><title>Incyte向FDA递交PD-1抗体上市申请，再鼎医药拥有中国权益</title><link>https://mp.weixin.qq.com/s/kD7szZ36wREGtU8BY4DEew</link><description></description><content:encoded><![CDATA[Incyte向FDA递交PD-1抗体上市申请，再鼎医药拥有中国权益]]></content:encoded><pubDate>Fri, 22 Jan 2021 19:52:58 +0800</pubDate></item><item><title>默克PD-L1/TGFβ双抗临床失败，国内多家药企在研</title><link>https://mp.weixin.qq.com/s/defcN2cQrJteNlk8M9U06Q</link><description></description><content:encoded><![CDATA[默克PD-L1/TGFβ双抗临床失败，国内多家药企在研]]></content:encoded><pubDate>Wed, 20 Jan 2021 23:34:27 +0800</pubDate></item><item><title>Merus与礼来达成16.8亿美元合作，贝达药业、先声药业均引进其双抗</title><link>https://mp.weixin.qq.com/s/ktxMT2516mHJasdLdsIbkQ</link><description></description><content:encoded><![CDATA[Merus与礼来达成16.8亿美元合作，贝达药业、先声药业均引进其双抗]]></content:encoded><pubDate>Wed, 20 Jan 2021 06:50:01 +0800</pubDate></item><item><title>CD47-SIRPα轴肿瘤免疫疗法：靶向SIRPα</title><link>https://mp.weixin.qq.com/s/aPa4bguxBDETWRbtFmMAaQ</link><description></description><content:encoded><![CDATA[CD47-SIRPα轴肿瘤免疫疗法：靶向SIRPα]]></content:encoded><pubDate>Wed, 20 Jan 2021 06:50:01 +0800</pubDate></item><item><title>国内首家：东阳光申报GLP-1/FGF21双功能分子</title><link>https://mp.weixin.qq.com/s/lH7r0aY4Iy91olis96_WVw</link><description></description><content:encoded><![CDATA[国内首家：东阳光申报GLP-1/FGF21双功能分子]]></content:encoded><pubDate>Wed, 20 Jan 2021 06:50:01 +0800</pubDate></item></channel></rss>